Superworth

CervoMed EPS CRVO

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Sep 30, 2024
n/m
a quarter missing
Latest quarter, Q3 FY24
−$0.55
Fiscal year 2018
$716666428.50

CervoMed's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY24, it was −$0.55.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2018$716666428.50n/a
FY2017−$3903.75n/a
FY2016−$1991.25n/a
FY2015−$3982.50n/a
FY2014−$267525.00n/a
FY2013−$3617437.50n/a
FY2012−$4500000.00n/a
FY2011n/an/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY24−$0.55n/an/a
Q3 FY23−$0.70n/an/a
Q3 FY22−$1.70−100%n/a
Q3 FY21$7642798425.00+59%n/a
Q2 FY21$7642798425.00+96%n/a
Q1 FY21$6256513800.00+142%n/a
Q3 FY20$4800850650.00+1264%n/a
Q2 FY20$3898371450.00+1219%n/a
Q1 FY20$2588062200.00+922%n/a
Q3 FY19$351996750.00+39%$900765178.50
Q2 FY19$295551300.00+17%$801628528.50
Q1 FY19$253217250.00+20%$758809978.50

Against its peers

Companies in Drug Manufacturers - General nearest CervoMed's size, closest first, today.

CompanyEPS, 12 monthsGrowth
CRVOCervoMedn/m
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on CervoMed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.